{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:47:58Z","timestamp":1793742478410,"version":"4.6.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaci.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T22:18:11Z","timestamp":1629757091000},"page":"927-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":403,"title":["JAK inhibitors in the treatment of atopic dermatitis"],"prefix":"10.1016","volume":"148","author":[{"given":"Raj","family":"Chovatiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.08.009_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.anai.2018.07.019","article-title":"Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy","volume":"121","author":"Hua","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2021.08.009_bib3","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jaip.2018.11.043","article-title":"Health utility scores of atopic dermatitis in US adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.08.009_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","article-title":"A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics","volume":"80","author":"Yew","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DER.0000000000000161","article-title":"Burden of sleep and fatigue in US adults with atopic dermatitis","volume":"27","author":"Yu","year":"2016","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2021.08.009_bib7","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.jaip.2019.05.055","article-title":"Pain is a common and burdensome symptom of atopic dermatitis in United States adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.08.009_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clindermatol.2017.03.008","article-title":"Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders","volume":"35","author":"Silverberg","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-016-0158-5","article-title":"Genetic and epigenetic studies of atopic dermatitis","volume":"12","author":"Bin","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2332\/allergolint.13-RAI-0564","article-title":"New insights into atopic dermatitis: role of skin barrier and immune dysregulation","volume":"62","author":"Leung","year":"2013","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2021.08.009_bib15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","article-title":"Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march","volume":"139","author":"Czarnowicki","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib16","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.009_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2019.09.031","article-title":"Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood","volume":"145","author":"Czarnowicki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib19","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2021.08.009_bib25","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"key":"10.1016\/j.jaci.2021.08.009_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib28","series-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","first-page":"657","author":"Wollenberg","year":"2018"},{"key":"10.1016\/j.jaci.2021.08.009_bib30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/archderm.136.8.999","article-title":"Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group","volume":"136","author":"Reitamo","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to\u00a0< 24 months with mild-to-moderate atopic dermatitis: a phase IV Open-Label Study (CrisADe CARE 1)","volume":"21","author":"Schlessinger","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib34","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jaad.2018.10.054","article-title":"A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor","volume":"80","author":"Pao-Ling Lin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib39","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.009_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.009_bib41","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2021.08.009_bib42","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib43","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jdermsci.2019.12.008","article-title":"Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model","volume":"97","author":"Yamamoto","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.08.009_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jdcr.2017.12.016","article-title":"Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor","volume":"4","author":"Morris","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2021.08.009_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2021.01.020","article-title":"Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy","volume":"10","author":"Peterson","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2021.08.009_bib50","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1002\/ccr3.3325","article-title":"Atopic dermatitis: tofacitinib, an option for refractory disease","volume":"8","author":"Berbert Ferreira","year":"2020","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaci.2021.08.009_bib51","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib53","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib54","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib55","first-page":"E116","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase III randomized double-blind studies","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib56","first-page":"AB121.57","article-title":"Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib57","first-page":"AB178.58","article-title":"Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib58","doi-asserted-by":"crossref","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Kuligowski ME, Venturanza M, et\u00a0al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: pooled analysis of two Phase 3, randomised, double-blind studies. Abstract (FC08.08) presented at: European Academy of Dermatology and Venereology Virtual Congress 2020.","DOI":"10.25251\/skin.5.supp.8"},{"key":"10.1016\/j.jaci.2021.08.009_bib59","first-page":"AB121.60","article-title":"Effect of ruxolitinib cream on sleep disturbance and sleep impairment: pooled analysis from two randomized phase 3 studies","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib60","doi-asserted-by":"crossref","first-page":"AB179","DOI":"10.1016\/j.jaad.2021.06.728","article-title":"Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Eichenfield","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib63","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study","volume":"178","author":"Nakagawa","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib64","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib65","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","article-title":"Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis","volume":"47","author":"Nakagawa","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib67","doi-asserted-by":"crossref","first-page":"AB52","DOI":"10.1016\/j.jaad.2021.06.235","article-title":"Delgocitinib ointment in pediatric patients with atopic\u00a0dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib69","doi-asserted-by":"crossref","first-page":"AB121","DOI":"10.1016\/j.jaad.2021.06.504","article-title":"A\u00a0phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI)","volume":"85","author":"Soerensen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib70","unstructured":"Landis M. A\u00a0Phase 2b study to evaluate the efficacy and safety of the topical TYK2\/JAK1 inhibitor brepocitinib for mild-to-moderate atopic dermatitis. Abstract (D1T03.4D) presented at: European Academy of Dermatology and Venereology Virtual Congress 2020."},{"key":"10.1016\/j.jaci.2021.08.009_bib71","doi-asserted-by":"crossref","first-page":"Ab170","DOI":"10.1016\/j.jaad.2020.06.770","article-title":"Safety of ATI-502, a novel topical JAK1\/3 inhibitor, in adults with moderate to severe atopic dermatitis: results from a phase 2a open-label trial","volume":"83","author":"Smith","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib74","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The Validated Investigator Global Assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib76","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib78","doi-asserted-by":"crossref","first-page":"AB113","DOI":"10.1016\/j.jaad.2021.06.470","article-title":"Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5","volume":"85","author":"Lio","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib80","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib81","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.17278","article-title":"Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomised trial","volume":"35","author":"Wollenberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.08.009_bib82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.08.009_bib83","doi-asserted-by":"crossref","first-page":"AB77","DOI":"10.1016\/j.jaad.2021.06.335","article-title":"Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib","volume":"85","author":"Gooderham","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib84","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","article-title":"Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical Trials","volume":"22","author":"King","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib85","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"10.1016\/j.jaci.2021.08.009_bib86","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.009_bib87","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results","volume":"14","author":"Silverberg","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib89","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/DER.0000000000000725","article-title":"Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib","author":"Simpson","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2021.08.009_bib91","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2021.08.009_bib93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdin.2021.05.004","article-title":"Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE","volume":"4","author":"Gooderham","year":"2021","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaci.2021.08.009_bib95","unstructured":"Reich K, de Bruin-Weller M, Deleuran MS, Beck LA, Papp KA, Werfel T, et\u00a0al. Abrocitinib efficacy and safety as monotherapy over 48 weeks: results from a long-term extension study. Abstract (D3T03.4C) presented at: European Academy of Dermatology and Venereology Virtual Congress 2020."},{"key":"10.1016\/j.jaci.2021.08.009_bib96","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.009_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2020.08.170","article-title":"Rapidity of efficacy response with abrocitinib versus dupilumab in the head-neck region (JADE COMPARE)","volume":"125","author":"Alexis","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib98","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.anai.2020.08.169","article-title":"Effective maintenance of response in atopic dermatitis patients after switching from dupilumab to abrocitinib (JADE-EXTEND)","volume":"125","author":"Bhutani","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib99","doi-asserted-by":"crossref","first-page":"Ab146","DOI":"10.1016\/j.jaci.2020.12.529","article-title":"Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis (AD): results from the phase 3 JADE TEEN study","volume":"147","author":"Eichenfield","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.009_bib101","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.009_bib102","unstructured":"Sofen H, Bissonnette R, Lee M, Zammit DJ, Jimenez Y, Chen Y, et\u00a0al. A\u00a0phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of gusacitinib (asn002) in subjects with moderate-to-severe chronic hand eczema. Abstract (D1T03.4C) presented\u00a0at: European Academy of Dermatology and Venereology Virtual Congress 2020."}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921012987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921012987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:31:26Z","timestamp":1758792686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921012987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0091674921012987"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors in the treatment of atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}